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Macular pigment measurements: which method
should we use?
Macular pigment (MP) was investi-
gated as early as 1866, when Max
Schultze concluded that there is a
functional connection between the
“yellow spot” in the retina and the
absorption of blue light. He stated that
MP may provide protection against
the hazard of short-wavelength visible
light. MP consists of the two hydroxy-
carotenoids lutein (L) and zeaxanthin
(Z) and is of is of alimentary origin.
Human MP is detectable in the whole
retina, but the highest concentrations
are found in the fovea [17]. As many
antioxidative properties are attributed
to the MP, it has been investigated in
respect to its role in the pathophysio-
logy of age-related macular degenera-
tion (ARMD). The properties of MP
include a high capacity to absorb short-
wavelength blue light [19]. The peak
of the MP absorbance spectrum is at
460 nm and works as a broad-band
filter for the macula. Two advantages
are achieved: (1) the macula’s optical
accuracy is improved [11, 16] and (2)
the damaging photooxidative influ-
ence on the neurosensory retina is
reduced. In the photoreceptor outer
segments, the antioxidant effect of
L and Z is the essential mechanism
[1, 22]. The antioxidant properties
enable the carotenoids to neutralize
free radicals.
The optical and antioxidant proper-
ties of MP, its possible relation to the
pathophysiology of ARMD, and the
possibility to modify macular pigment
optical density (MPOD) by nutritional
supplementation have resulted in a
growing interest in research on MP.
This is reflected by a growing number
of papers on MP during recent years.
MPOD can be measured by psy-
chophysical and optical means. These
include heterochromatic flicker
photometry [12, 24] and minimum
motion photometry [23], Raman
spectrometry [8, 9, 14], imaging
reflectometry [3, 13], reflectometry
[4, 27], and autofluorescence spectro-
photometry [12] and imaging [6, 23,
26]. This large number of different
methods may explain the inconsisten-
cies between papers on MPOD in
patients with various stages of ARMD
[1, 2, 5, 7, 10, 15, 16, 18, 19, 21, 24].
The current issue presents a paper in
which Trieschmann et al. [25] present
MPOD measurements using autofluo-
rescence images. They compare a
method [27] based on pioneering work
from Delori et al. [12] using autofluo-
rescence images obtained at two
wavelengths (488 nm and 514 nm) by
means of a method presented by the
same group previously [23, 26] using
autofluorescence images obtained at
one wavelength (488 nm). They
describe in great detail the theory of
MPOD measurements using autofluo-
rescence imaging, repeating previous
work [12]. In their manuscript they
conclude that the one-wavelength
method is adequate for visualizing the
MP but not for determining MPOD,
whereas the two-wavelength method
allows for accurate determination of
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MPOD. These conclusions are mainly
based on the theoretical considerations
presented in the methods section.
However, the actual measurements
presented in the paper do not permit
these conclusions. There is no
evidence that one method is better than
the other, since no comparison with an
independent measure of MPOD based
on a more established technique such
as psychophysics is presented in the
manuscript. However, recently a
comparison between the two-wave-
length method using autofluorescence
imaging (AF) and the heterochromatic
flicker photometry (HFP) technique
has been published [20]. In this paper
no correlation between the two meth-
ods was presented. However, the large
difference in the coefficient of varia-
tion for repeated measurement be-
tween the two methods (16.6% for
HFP vs 3.3% for AF) suggests that the
two-wavelength AF method is more
precise than the HFP method for
determination of MPOD [20].
Recent work suggests that the dis-
tribution of MP could be more
important than central MPOD [6, 18,
23]. Therefore, future studies on MP
should use a method allowing mea-
surement not only of MPOD in the
foveal center but also of MP distribu-
tion. Since the determination of MP
distribution with psychophysical
methods is difficult and very time
consuming, MPOD measurement by
imaging methods appears to be more
suitable for clinical studies. The the-
oretical considerations presented in
the paper by Trieschmann et al. [25]
suggest that we should abandon the
one-wavelength AF method and use
only the two-wavelength method for
future studies.
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